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Abstract
Thymic stromal lymphopoietin (TSLP), a novel interleukin-7-like cytokine, triggers dendritic cell-
mediated inflammatory responses ultimately executed by T helper cells of the Th2 subtype. TSLP
emerged as a central player in the development of allergic symptoms, especially in the airways, and
is a prime regulatory cytokine at the interface of virus- or antigen-exposed epithelial cells and
dendritic cells (DCs). DCs activated by epithelium-derived TSLP can promote naïve CD4+ T cells
to adopt a Th2 phenotype, which in turn recruite eosinophilic and basophilic granulocytes as well
as mast cells into the airway mucosa. These different cells secrete inflammatory cytokines and
chemokines operative in inducing an allergic inflammation and atopic asthma. TSLP is, thus, involved
in the control of both an innate and an adaptive immune response. Since TSLP links contact of
allergen with the airway epithelium to the onset and maintainance of the asthmatic syndrome,
defining the signal transduction underlying TSLP expression and function is of profound interest for
a better understandimg of the disease and for the development of new therapeutics.
Background
Atopic asthma is a common inflammatory disorder of the
airway epithelium characterized by tissue obstruction and
remodeling, bronchial smooth muscle cell hyperreactivity
to allergens and chronic bronchial inflammation. It clas-
sically involves allergen-driven T helper 2 (Th2) lym-
phocyte polarisation with coordinate production of
interleukin (IL)-4, IL-5, IL-13 and granulocyte-macro-
phage colony-stimulating factor (GM-CSF), which are
encoded in one gene cluster on chromosome 5q31-34 [1].
IL-4 and IL-13 are critically involved in the pathogenesis
of allergic asthma by regulating IgE-production by B cells,
inducing airway hyperreactivity and triggering key fea-
tures of airway remodeling, whereas IL-5 is a key factor for
eosinophilia [2,3]. Activation of IgE receptors on mast
cells triggers the release of preformed vasoactive media-
tors such as histamine, the synthesis of prostaglandins
and leukotrienes, and, via a positive feedback loop,
expression IL-4 and IL-13 [2].
Its apparent association with airway diseases has recently
focussed interest on the novel IL-7-like cytokine thymic
stromal lymphopoietin (TSLP). TSLP expression is
increased in asthmatic airways and correlates with both
the expression of Th2-attracting chemokines and with dis-
ease severity [4-6], indicating a link between TSLP and
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mental lung-specific expression of TSLP leads to trans-
gene-induced allergic airway inflammation characterized
by a massive infiltration of leukocytes, goblet cell hyper-
plasia, and subepithelial fibrosis, as well as by increased
serum IgE levels [7].
TSLP is a typical four-helix-bundle cytokine 140 amino
acid residues in length and was first cloned in humans in
2001 [8-10]. The human TSLP gene is localized on chro-
mosome 5q22, interestingly close to the gene cluster
encoding several Th2-related cytokines such as IL-4, IL-5,
IL-9, and IL-13 [7,11]. Human TSLP is produced by differ-
ent cell types in atopic asthma, mainly by epithelial and
smooth muscle cells and induces an inflammatory Th2
response. The TSLP receptor (TSLPR) is a heterodimeric
cytokine receptor consisting of the IL-7 receptor alpha
chain (IL-7Rα) and a TSLP-specific receptor chain with
similarity to the common gamma receptor chain (γc). The
TSLPR, also known as CRLF2, is expressed in heart, skele-
tal muscle, kidney and liver, but also on asthma-relevant
dentritic cells [9,12]. In this review, the signal transduc-
tion around human TSLP in the cascade of events in the
development of atopic asthma is discussed. We first
describe the regulation of TSLP production in airway epi-
thelial and other cells, then cover the TSLPR-mediated
effects on TSLP target cells such as DCs and mast cells, and
finally treat the DC-triggered onset of a specific Th2
response.
Regulation of TSLP expression
In the human airway system, fibroblasts, smooth muscle
cells, epithelial cells and mast cells all have the potential
to produce TSLP [14-18]. Airway epithelial cells (AECs)
were found to have increased TSLP mRNA levels in
human asthmatics [4]. Importantly, overexpression of
TSLP in AECs induces experimental asthma in mice [7].
TSLP expression is enhanced by different stimuli with rel-
evance in asthma. Primary small airway epithelial cells
(SAECs) produce biologically active TSLP in response to
bacterial peptidoglycan, and lipoteichoic acid as well as to
poly I:C (mimicking viral double-stranded RNA) [16]. IL-
1β and TNF-α, two cytokines associated with pulmonary
inflammation and strongly upregulated in the asthmatic
lung [19,20] can, under appropriate conditions, induce
human TSLP expression in normal human bronchial epi-
thelial cells (NHBECs) [15,17], SAECs [16] and human
airway smooth muscle cells (HASMCs) [18]. Similarly,
TGF-β, IFN-β, IL-4, IL-13, and, in particular, a combina-
tion of TNF-α and IL-4 or IL-13 upregulate TSLP expres-
sion in NHBEs [17].
It is established that rhinovirus and respiratory syncytial
virus (RSV) can trigger exacerbations of asthma [21]. TSLP
expression in human bronchial epithelial cells is stimu-
lated by both viruses and an involvement of signal trans-
duction through p38 and Jun kinase (JNK) has been
demonstrated [22]. Stimulation of TSLP expression
evoked by rhinoviral dsRNA and RSV proteins via toll-like
receptors (TLRs) is synergistically enhanced by IL-4, indi-
cating a contribution of JAK/STAT signalling [17]. The
notion of cooperative signalling to TSLP gene transcrip-
tion by cytokine and toll-like receptors is supported by the
observation that tumor necrosis factor- (TNF-) α and IL-4
or IL-13 jointly drive TSLP expression in NHBECs, but
none of the factors has a respective effect on its own. The
induction of TSLP by combination of TNF-α and Th2
cytokines but not by the individual cytokines suggests that
NFκB and STATs cooperate in transcriptional regulation
of the TSLP gene [17].
HASMCs which also act as effector cells in initiating or
perpetuating airway inflammation [23,24], respond by
TSLP release to stimulation with TNF-α and IL-1β both in
vitro and in vivo [18]. Pharmacological inhibitors of ERK1/
2 and p38, but not blockers of phosphatidylinositid-3
kinase (PI-3K) specifically suppress TSLP secretion
induced by both factors individually or combination, sug-
gesting that TSLP expression in HASMC is controlled via
MAPK pathways [18]. Crosstalk of NFκB- and MAPK path-
ways is suggested by experiments in cells with mutated
mediators NFκB and Ras which show a strong decrease in
transcriptional activity of the human TSLP promoter [25].
Studies employing deletion constructs of the TSLP gene
promoter indicated that a DNA fragment extending from
3.74 to 3.86 kb upstream of the transcriptional start site
contains a cis element required for transcriptional induc-
tion by IL-1β. Inspection of this ~120-bp sequence
revealed consensus cognate elements for NFκB and IRF-1
as well as a putative AP-1 binding site [15]. Mutations in
these motifs indicated that the induction of TSLP gene
expression seen in cells stimulated with IL-1β is likely to
be mediated through NFκB, whose subunits p65/p50
bind to the NFκB cognate motif in the human TSLP pro-
moter. One of the major pathways for NFκB activation
involves the phosphorylation of the inhibitor IκBα, which
is followed by IκBα degradation and the subsequent
migration of NFκB dimers (each monomer consisting of a
p50 and a p65 subunit) from cytoplasm to the nucleus
[26]. A dominant-negative mutant of IKKβ (IκB) inhibits
IL-1β-mediated transcription of the TSLP gene [15].
Since TLSP induction in the airway epithelium of asthmat-
ics appears to be a associated with allergen contact, it is
important to note that engagement of TLRs by allergene
provocation activates NFκB [27]. TLR2, TLR3, TLR8, and
TLR9 can all induce human TSLP expression in airway epi-
thelial cells [15,17], suggesting that TSLP may becomePage 2 of 8
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lenge. In line with this hypothesis, we have recently
observed that direct stimulation of lung epithelial cells
with different allergens induces the expression of TSLP
mRNA (Borowski et al., manuscript in preparation).
Viral dsRNA is sensed, apart from TLR3, also by the
recently identified cytosolic RNA helicases RIG-I and
MDA5 [28,29]. Activation of TLR3, RIG-I, and MDA5 by
dsRNA is transmitted to transcription factors NFκB and
IRF-3, leading to transcriptional upregulation of pro-
inflammatory genes and expression of type I interferons
including IFN-β. siRNA experiments suggested that TSLP
is directly induced by dsRNA in airway epithelial cells, and
that the response is mediated by a pathway involving
TLR3, NFκB and and IRF-3, but is independent of inter-
feron signalling. Enhancement of dsRNA-dependent TSLP
expression by IL-4 is significantly inhibited by siRNA tar-
geting STAT6, supporting the notion of STAT6 as an
important transcription factor in the control of TSLP
expression [17].
Very recent work showed that TSLP expression in the
murine lung is influenced by peptidyl-propyl isomerase
(PIN1), an important regulator of survival-promoting and
proinflammatory cytokines in T-cells. Active PIN1 inacti-
vates adenosine-uridine binding factor 1 (AUF1), whose
function is to destabilize mRNA by interaction with ade-
nosine-uridine rich elements. Since TSLP expression is
blocked by a PIN1 inhibitor after challenging lung with
allerges and the 3'-untranslated region of TSLP mRNA
contain an AUF1 binding site, PIN1 is likely to be a mod-
ulator of TSLP expression in asthma at the posttranscrip-
tional level [30].
Activation of the TSLP receptor and intracellular signal 
transduction
The specific, low affinity TSLP receptor α chain (TSLPRα)
is a member of the hematopoietic (type 1) cytokine recep-
tor family. In combination with the IL-7Rα chain it forms
the heterodimeric TSLP receptor (TSLPR) which, upon
TSLP binding, transmits signals towards STAT activation
and proliferation into the cell interior [8,9,31,32]. The
TSLPRα chain has some atypical features for a type 1
cytokine receptor, both in its extracellular and intracellu-
lar region. The exodomain, for instance, lacks one of the
four cysteine residues conserved within the receptor fam-
ily, perhaps indicating a unique tertiary structure. Intracel-
lularly, the TSLPRα lacks one of the two conserved
sequence boxes present in other cytokine receptors that
govern the interaction with Janus kinases (JAKs).
Signal transduction emanating from the dimerized TSLPR
is similar to signalling from the IL-7R, reflecting the over-
lapping utilization of the IL-7Rα chain by the two sys-
tems. The IL-7 receptor utilizes the γc chain as a
dimerization partner for IL-7Rα, which recruits JAK3 via
its box1 element. Ligand-induced crosslinking of both the
TSLP and IL-7 receptors results in the activation of STAT5
and STAT3 and concomitant specific gene regulation
[8,33,34]. However, unlike the IL-7R, the TSLPR appears
to drive STAT activity via an uncommon mechanism with-
out an involvement of Janus kinases. Evidence for this
interpretation comes from experiments showing that no
JAK phosphorylation was evoked by the activated TSLPR
and that dominant-negative forms of JAK1 and JAK2 did
not block TSLP-mediated STAT5 activation [35]. It was
puzzling, however, that fusions of TSLPR cytoplasmic
domain with the exodomains of the erythropoietin recep-
tor or CD8 did activate JAK2 upon ligand-dependent
homo-dimerization [36-38]. From results obtained with
dominant-negative versions of Tec, a role of this cytoplas-
mic Src-related tyrosine kinase in the TSLPR-mediated
activation of STAT5 was inferred [33]. Src-type mediators
are also involved in proliferative signaling, TSLP-induced
cell proliferation is blocked by the Src family inhibitor
PP1 [34]. While both STAT5 activation and cell prolifera-
tion require the box1 domain of TSLPRα and IL-7Rα, the
single intracellular tyrosine residue of TSLPRα receptor is
critical only for proliferative signaling, but not for TSLP-
dependent STAT5 activation [34]. Apart from STAT5, TSLP
initiates STAT3 phosphorylation in murine DCs without
the induction of any of the four Janus kinases (JAKs)
[9,31,32] and activates STAT1 in murine pro B cells (A.
Wohlmann and K. Friedrich, unpublished results). TSLP
does not stimulate the activation of ERK1/2 and p70S6K
[8]. Thus, neither the MAPK pathway nor the p70S6K
pathway appear to be involved in the signal transduction
pathway elicited by TSLP. Details of TSLPR signaling are
far from being settled, but the present view is that Src type
kinases are mediating the proliferative response and
unknown (non-JAK) kinases are critical for STAT activa-
tion and, ultimately, regulation of target genes (Figure 1).
Activation of effector cells of the innate and adaptive 
immune system through TSLP
Compelling evidence has been acumulated for a determi-
native role of TSLP in the initiation and maintenance of
the allergic response in the context of atopic asthma [5,6].
Human TSLP is able to directly activate effector cells of the
innate immune system like mast cells (MCs), which are
known to play an important role in the pathogenesis of
atopic diseases [39,40]. Functional receptors for TSLP are
expressed in vivo on MCs infiltrating the bronchial mucosa
of asthmatic patients as revealed by immunostaining of
biopsy specimen [16]. In inflammatory conditions mim-
icked by the presence of IL-1 and TNF α, TSLP is a potent
activator of MCs leading to the production of high levels
of proinflammatory Th2 cytokines and chemokines such
as IL-5, IL-13, IL-6, GM-CSF, CXCL8, and CCL1 [16] (Fig-Page 3 of 8
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regulation have not been characterized yet.
Apart from mast cells, the second main sentinel of the
innate immune system is represented by DCs localized at
the epithelial surface. DCs are also operative in the crea-
tion of a microenvironment that directs T cells towards
Th1 or Th2 differentiation. A strong Th2 type response is
typical in the context of the allergic syndrome. Human
TSLP strongly activates immature CD11c+ DCs while it
does not appear to have any direct biological effects on B
cells, T cells, NK-cells or neutrophils [9,14,41]. TSLP
induces DCs to up-regulate the expression of major histo-
compatibility class I and II and costimulatory molecules,
including CD40, CD80, CD86. Importantly, it also
strongly upregulates expression of the mRNA for OX40L,
a member of the TNF superfamily that has been impli-
cated in the initiation of Th2 cell responses [42-44]. TSLP
also stimulates DCs to produce the Th2-attracting chem-
okines TARC (thymus and activation regulated chemok-
ine, CCL17) and MDC (macrophage derived chemokine,
CCL22) [14], as well as IL-8, IL-15 and eotaxin-2, clearly
suggesting that TSLP-activated DCs may represent an ini-
tial key step in the development of allergic inflammation
[34,45]. In the asthmatic bronchial mucosa, elevated
expression of TSLP was also accompanied by and corre-
lated with elevated expression of the CCR4 ligands TARC
and MDC at the mRNA level [4]. As revealed by a compar-
ative global transcriptome analysis of naive and TSLP
treated DCs, TSLP does not stimulate DCs to produce the
Th2-polarizing cytokine IL-4 and, at the same time, sup-
presses the anti-inflammatory cytokine IL-10 as well as
interferon- (IFN-) γ [45].
When TSLP treated DCs are stimulated with CD40 ligand,
they induce the differentiation of CD8+ T cells into cyto-
lytic effector cells which produce IFN-γ as well IL-4 and IL-
13. Interestingly, expression of these ctokines has as
before been considered mutually exclusive [46] (Figure
2).
Structure and signal transduction of the heterodimeric TSLP receptor complexFigure 1
Structure and signal transduction of the heterodimeric TSLP receptor complex. For details see text.Page 4 of 8
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OX40L, a member of the TNF superfamily has been iden-
tified as crucial mediator of Th2 cell responses driven by
DCs [43,47]. In mice, blocking of OX40L by inhibitory
antibodies inhibited the immune response induced by
TSLP, indicated by reduction of cytokine secretion, Th2
inflammatory cell infiltration and IgE production [48]. It
appears that OX40L and IL-4 act synergistically and
sequentially in driving Th2 cell responses in cocultures of
T cell and DCs activated by TSLP [10,45]. Interestingly, in
the presence of IL-12, OX40L is unable to induce a Th2
cell response but rather directs T cell differentiation
towards the Th1 phenotype, indicating a functional dom-
inance of IL-12 over TSLP [45].
Historically, CD4+ Th2 cells are defined as effector T cells
with the capacity to produce IL-4, -5, -10, and -13 [49,50].
IL-4 and IL-13 are typical pro-inflammatory cytokines, but
IL-10 does not appear to contribute to allergic inflamma-
tion in either humans or mice [51,52], but even sup-
presses allergic inflammation [53-55]. Importantly,
dendritic cells activated by TSLP prime naive CD4+ T cells
to differentiate into a particular subtype of Th2 cells that
produce the classical Th2 cytokines IL-4, IL-5 and IL-13,
but no IL-10. It is also remarkable that these special Th2
cells secrete very high levels of TNF-α [14]. TNF-α is prom-
inent in asthmatic airways and genotypes that correlate
with increased TNF-α secretion are associated with an
increased risk of asthma [56]. Because of their unique pro-
file of cytokine production, Th2 cells induced by TSLP-
activated DCs have been designated inflammatory Th2
cells to discriminate them from the classical regulatory
Th2 cells [10] (Figure 2).
Th1 and Th2 cell differentiation is regulated by the key
transcription factors T-bet for Th1 and GATA-3 and c-Maf
for Th2. Th1 cells express high levels of T-bet but low
GATA-3 and c-Maf, while Th2 cells show a reverse expres-
Central role of TSLP in the orchestration of an asthmatic response upon contact of the airway epithelium with allergens or other challenging agentsFigu e 2
Central role of TSLP in the orchestration of an asthmatic response upon contact of the airway epithelium with 
allergens or other challenging agents. Intercellular communication among different cell types via cytokines evokes activity 
of the native (bottom part) as well as the adaptive (upper part) of the immune system. For details see text.Page 5 of 8
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as molecular markers for Th1 or Th2 cells [57]. CD4+ T
cells primed by TSLP-activated DCs show the typical Th2
pattern high GATA-3 and c-Maf and low T-bet. However,
IL-12 can override this Th2-specific gene regulation by
inhibiting GATA-3 and c-Maf and strongly up-regulating
T-bet [Ito et al. 2005]. Regulation processes behind this
phenomenon may involve temporal IL-12-induced upreg-
ulation of the IL-12R signaling subunit (IL-12Rβ2) and
concomitant signal transduction via STAT4, which has
been observed in CD4+ cells upon activation of OX40
[58].
TSLP has also been discussed as a player in the mainte-
nance and regulation of Th2 memory cells. This interpre-
tation comes from the finding that DCs activated by TSLP
can induce an expansion of a CD4+ T cell subset express-
ing the prostaglandin D2 receptor (CRTH2), a property of
human Th2 central memory T cells [59]. Interestingly,
TSLP-activated DCs enhance the allergy-inducing proper-
ties of Th2 memory cells by up-regulating their expression
of pro-allergic genes, particularly IL-17RB, the receptor for
IL-25. IL-25, in turn, was shown to trigger the prolifera-
tion of Th2 memory cells and increase to the production
of IL-4, IL-5, and IL-13, but not TNF-α or IFN-γ. These
results suggest that IL-25 may costimulate the prolifera-
tion and further polarization of Th2 memory cells
induced by TSLP-activated DCs [60].
Importantly for the development of asthmatic symptoms,
the activation of inflammatory Th2 cells through TSLP
and their production of the inflammatory cytokines IL-4,
IL-5, IL-13 and TNF-α triggers IgE production, eosi-
nophilia, mucus production and fibroblast proliferation
[61,62]. The effector mechanisms of atopic asthma ulti-
mately involve IgE-coated mast cells that undergo degran-
ulation upon contact with the allergen and induce an
immediate response, leading to the symptoms of local
inflammation and bronchospasm [63].
Conclusion
In atopic asthma, many different agents such as viruses,
bacteria and allergens can induce a TSLP-dependent
inflammatory response, leading to an inappropriate acti-
vation of both the innate and the adaptive immune sys-
tem. With regard to the innate branch of the response,
TSLP acts on mast cells and dendritic cells as well as,
according to recent results, natural killer cells. Mast cells
play a prominent role in the development of asthmatic
symptoms, because they secrete inflammatory cytokines
in response to TSLP. The fact that mast cells also produce
TSLP indicates a potential amplification loop by the
action of mast cell-derived TSLP on epithelial DCs. A crit-
ical switch governed by DCs is the TSLP-induced expres-
sion of OX40L, a Th2 cell polarizing signalling molecule.
A further emerging role of TSLP is the generation of Th2
memory T cells. The IL-25-mediated collaborative interac-
tions between eosinophils/basophils and Th2 memory
cells perhaps propagate a positive feedback loop between
innate effector and adaptive immunity, leading to the
amplification of allergic inflammation (Figure 2).
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